Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
The agreement sets terms under which POC will manufacture the product or receive royalties
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated